Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
7%
Alpha Tocotrienol
11%
Bevacizumab
25%
Biliary Tract Cancer
11%
Biological Marker
58%
Breast Cancer
11%
Capecitabine
13%
Carboplatin
7%
Cetuximab
8%
Chemoradiation Therapy
11%
Chemotherapy
62%
Circulating Tumor DNA
85%
Colon Carcinoma
11%
Colorectal Carcinoma
37%
Combination Therapy
8%
Diseases
21%
DNA A
5%
Epidermal Growth Factor
12%
Epidermal Growth Factor Receptor
23%
Gemcitabine
11%
Interleukin 6
10%
Irinotecan
22%
Lung Cancer
14%
Malignant Neoplasm
26%
Metastatic Colorectal Cancer
94%
microRNA
11%
Monotherapy
7%
Neoplasm
100%
Neuropeptide Y
10%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
9%
Non Small Cell Lung Cancer
12%
Ovary Cancer
31%
Ovary Carcinoma
19%
Ovary Tumor
7%
Overall Survival
69%
Oxaliplatin
8%
Pancreas Cancer
11%
Phase II Trials
23%
Postcholecystectomy Syndrome
5%
Progression Free Survival
51%
Prospective Study
8%
Receptor
9%
Rectum Cancer
17%
Recurrent Disease
8%
Regorafenib
5%
SARS Coronavirus
5%
Solid Malignant Neoplasm
10%
Tumor Marker
8%
Vasculotropin
11%
Vasculotropin A
8%
Biochemistry, Genetics and Molecular Biology
Allele
11%
Bevacizumab
17%
Blood Plasma
77%
Capecitabine
13%
Cell Activity
10%
Circulating Tumor DNA
98%
Clinical Trial
8%
Cochrane Library
7%
Colon
12%
Computer Assisted Tomography
7%
Copurification
6%
Diagnostic Biomarker
7%
DNA Analysis
9%
DNA Methylation
19%
DnaA
5%
Droplet Digital Polymerase Chain Reaction
34%
Dynamics
15%
Embase
10%
Epidermal Growth Factor
5%
Epidermal Growth Factor Receptor
8%
Exon
5%
Gemcitabine
11%
Gene Polymorphism
7%
Genetic Marker
7%
Genotyping
18%
Growth Factor-Like Domain
5%
Homeobox
29%
HOXA9
42%
Intracellular Signaling
5%
Kinase Insert Domain Receptor
7%
KRAS
32%
Medline
9%
Methylation
52%
MicroRNA
29%
Multivariate Analysis
10%
Natural Killer Cell
11%
Overall Survival
50%
Patient Coding
5%
Phase II Trials
8%
Poly ADP Ribose Polymerase
11%
Progression Free Survival
37%
Quantitative Technique
6%
Real-Time Polymerase Chain Reaction
21%
Single-Nucleotide Polymorphism
39%
TaqMan
7%
Tumor Marker
5%
Vascular Endothelial Growth Factor
17%
Vascular Endothelial Growth Factor A
18%
Web of Science
7%
Wild Type
14%
Medicine and Dentistry
Alpha Tocotrienol
5%
Antisense
5%
Arm
5%
Bevacizumab
11%
Biliary Tract Cancer
11%
Biological Marker
30%
Breast Cancer
11%
Cancer
9%
Cancer Diagnosis
8%
Capecitabine
11%
Cell-Free DNA
45%
Chemoradiotherapy
17%
Circulating Tumor DNA
61%
Colorectal Carcinoma
46%
Diseases
11%
DNA Methylation
12%
Droplet Digital Polymerase Chain Reaction
28%
Epidermal Growth Factor Receptor
5%
Erlotinib
5%
Gemcitabine
11%
Gene Expression
9%
Hazard Ratio
8%
High Risk Population
6%
Homeobox
11%
Irinotecan
7%
Krukenberg Tumor
10%
Lung Cancer
23%
Lung Metastasis
8%
Malignant Neoplasm
17%
Meta-Analysis
23%
Metastatic Carcinoma
15%
Metastatic Colorectal Cancer
19%
Methylation
37%
microRNA 21
7%
Multivariate Analysis
7%
Neoadjuvant Therapy
7%
Neoplasm
28%
Ovarian Cancer
23%
Ovarian Tumor
7%
Overall Survival
26%
Phase II Trials
8%
Progression Free Survival
25%
Prospective Study
6%
Real-Time Polymerase Chain Reaction
8%
Receptor
9%
Rectum Cancer
25%
Reproducibility
6%
Specific Tumor
30%
Systematic Review
23%
Treatment Response
10%
